Sign In
Buy ACRV
$1.63
+0.0500 (+3.16%)
At Close: Jun 23, 2026
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
07:30am, Thursday, 21'st May 2026
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and devel
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 15'th May 2026
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and devel
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
04:10pm, Wednesday, 13'th May 2026
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms i
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 15'th Apr 2026
WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and dev
Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% – Still a Buy?
02:58am, Tuesday, 14'th Apr 2026
Shares of Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) were up 3.2% on Monday. The stock traded as high as $1.64 and last traded at $1.61. Approximately 865,467 shares traded hands duri
Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)
01:28am, Wednesday, 01'st Apr 2026
Acrivon Therapeutics (NASDAQ: ACRV - Get Free Report) and Oasmia Pharmaceutical (OTCMKTS:OASMY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will comp
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
07:21am, Thursday, 19'th Mar 2026
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC)
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (A
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 03'rd Mar 2026
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
05:05am, Monday, 02'nd Mar 2026
Acrivon Therapeutics (NASDAQ: ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company's ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, wit
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
08:00am, Tuesday, 24'th Feb 2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and deve
Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
08:00am, Wednesday, 18'th Feb 2026
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational an
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update
02:34am, Thursday, 12'th Feb 2026
Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) saw a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 2,024,627 shares, a de
